The race to develop medicines that target cancer has become more competitive, but it is one that has mostly been welcomed by the capital markets.
Chinese precision medicine developer 3D Medicines, also called 3DMed, is in the process of a $60 million Series A fundraising for its cancer drug research business.
In an exclusive interview with FinanceAsia, John Gong, chief executive of 3DMed, said that the company aims to complete another round of pre-IPO funding by the end of the year. And with around $150 million funding under its belt, it is looking to IPO in Hong Kong in the second or third quarter of...
¬ Haymarket Media Limited. All rights reserved.
